Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as the French drugmaker tries to expand a vaccines business currently anchored by its flu shot franchise. The announcement came after the US Food and Drug Administration surprisingly rejected Sanofi’s experimental multiple sclerosis drug tolebrutinib. Bloomberg’s Ashleigh Furlong reports.
www.bloomberg.com
#Sanofi #Buy #Dynavax #Boost #Vaccines #Business
Sanofi to Buy Dynavax to Boost Vaccines Business
